Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel leukocyte extract mixed factor and preparation method thereof

A technology of mixing factors and extracts, which is applied in the direction of drug combinations, pharmaceutical formulas, peptide/protein components, etc., to achieve the effects of accelerating regulation, improving therapeutic effects, and increasing powder output

Inactive Publication Date: 2021-05-28
宏之俊生物科技(上海)有限公司
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The mixed application of white blood cell extract still needs to be expanded

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel leukocyte extract mixed factor and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] A novel leukocyte extract mixed factor, according to volume percentage, comprises 27 parts of leukocyte extract, 33 parts of platelet lysate, 10 parts of interleukin, 25 parts of stem cell extract, and 5 parts of leukocyte.

[0019] In this example, the selected interleukins are derived from the interleukin-1 family, including IL-1α, IL-1β, IL-1 receptor antagonists, IL-18, IL-36Ra, IL-36α, IL -37, IL-36β, IL-36γ, IL-38 and IL-33, specifically, the mixture of IL-18, IL-36Ra, IL-36α and IL-37 was used in this example.

[0020] In this embodiment, the whitening substances include bisbenzylisoquinoline alkaloids, rubic acid derivatives and synergists; the mass mixing ratio of bisbenzyl isoquinoline alkaloids and rubic acid derivatives is 1:4 .

[0021] In this embodiment, the synergist includes rutabine, anisene, and aminopeptide, and the mass mixing ratio of rutileside, anisene, and aminopeptide is 2:2:3.

[0022] In the present embodiment, the mixed factor in the prese...

Embodiment 2

[0026] A novel leukocyte extract mixed factor, according to volume percentage, comprises 15 parts of leukocyte extract, 25 parts of platelet lysate, 5 parts of interleukin, 22 parts of stem cell extract, and 23 parts of white matter.

[0027] In this example, the selected interleukins are derived from the interleukin-1 family, including IL-1α, IL-1β, IL-1 receptor antagonists, IL-18, IL-36Ra, IL-36α, IL -37, IL-36β, IL-36γ, IL-38 and IL-33, specifically a mixture of IL-18, IL-36Ra, IL-36α, IL-37.

[0028] In this embodiment, the whitening substances include bisbenzylisoquinoline alkaloids, rubic acid derivatives and synergists; the mass mixing ratio of bisbenzyl isoquinoline alkaloids and rubic acid derivatives is 1:4 .

[0029] In this embodiment, the synergist includes rutabine, anisene, and aminopeptide, and the mass mixing ratio of rutileside, anisene, and aminopeptide is 2:2:3.

[0030] In the present embodiment, the mixed factor in the present invention is suitable for...

Embodiment 3

[0034] A novel leukocyte extract mixed factor, according to volume percentage, comprises 25 parts of leukocyte extract, 30 parts of platelet lysate, 7 parts of interleukin, 23 parts of stem cell extract, and 15 parts of white matter.

[0035] In this example, the selected interleukins are derived from the interleukin-1 family, including IL-1α, IL-1β, IL-1 receptor antagonists, IL-18, IL-36Ra, IL-36α, IL -37, IL-36β, IL-36γ, IL-38 and IL-33; specifically a mixture of IL-18, IL-36Ra, IL-36α, IL-37, IL-36β.

[0036] In this embodiment, the whitening substances include bisbenzylisoquinoline alkaloids, rubic acid derivatives and synergists; the mass mixing ratio of bisbenzyl isoquinoline alkaloids and rubic acid derivatives is 1:4 .

[0037] In this embodiment, the synergist includes rutabine, anisene, and aminopeptide, and the mass mixing ratio of rutileside, anisene, and aminopeptide is 2:2:3.

[0038] In the present embodiment, the mixed factor in the present invention is suit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a novel leukocyte extract mixed factor which comprises the following components in percentage by volume: 15-27 parts of leukocyte extract, 25-33 parts of platelet lysate, 5-10 parts of interleukin, 22-25 parts of stem cell extract and 5-23 parts of leukocyte increasing substance. The invention also discloses a preparation method of the novel leukocyte extract mixed factor. The preparation method comprises the following steps: S1, preparing the leukocyte extract; S2, preparing a platelet lysate; S3, preparing a mixed factor; and S4, drying a finished product; the leukocyte increasing substance is added into the leukocyte extract, so that after mixed factors enter animal bodies on the basis of healing of the leukocyte extract, the generation quantity of leukocytes and the maturation speed of the leukocytes are increased, and inflammation healing and immunocompetence regulation are accelerated; in the preparation process of the mixed factor, the leukocyte is cultured to supplement nucleotide and leukocyte factors, so that the powder yield of the mixed factor can be increased, the treatment effect can be improved, and the treatment effect can be more stably exerted.

Description

technical field [0001] The invention relates to the field of cell extraction, in particular to a novel leukocyte extract mixed factor and a preparation method of a novel leukocyte extract mixed factor. Background technique [0002] White blood cells are divided into neutrophils, eosinophils, basophils, monocytes, and lymphocytes. The first three are called granulocytes because they contain chromophilic granules in their cytoplasm. It can be seen under a microscope that blood cells are relatively large in volume, relatively few in number, and have a nucleus. Its main role is to phagocytose bacteria and defend against disease. White blood cells can phagocytose foreign bodies, and plasma cells produce antibodies, which play an important role in healing the body's damage, resisting the invasion of pathogens, and immunizing against diseases. [0003] Interleukins are a class of cytokines that are produced by and act on a variety of cells. At least 38 interleukins have been dis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K35/15A61K35/19A61K35/28A61K38/20A61P17/00A61P29/00A61P37/04
CPCA61K45/06A61K35/15A61K35/19A61K35/28A61K38/20A61P37/04A61P17/00A61P29/00
Inventor 朱晗
Owner 宏之俊生物科技(上海)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com